Amgen Introduces Direct-to-Patient Access for Repatha in US

Amgen (AMGN) said Monday it launched AmgenNow, a direct-to-patient program in the US starting with its cholesterol drug Repatha, or evolucumab.

The company said eligible patients can buy Repatha through the program for $239 per month, about 60% lower than the drug's current list price. The program is open to patients who are uninsured, in high-deductible health plans, or prefer to pay out of pocket, according to Amgen.

The program will be available to all Repatha patients, including those on Medicare and Medicaid, and will not require step therapy or prior authorization, the company said.

Price: 297.00, Change: -0.89, Percent Change: -0.30